Literature DB >> 28968800

The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation.

Mélanie Drolet1, Jean-François Laprise1, Julia M L Brotherton2,3, Basil Donovan4, Christopher K Fairley5, Hammad Ali4, Élodie Bénard1, Dave Martin1, Marc Brisson1,6,7.   

Abstract

We used transmission-dynamic modeling to estimate the added effectiveness of vaccinating multiple cohorts of females (12-26 years) in Australia compared with the theoretical introduction of routine-only (12-13 years) vaccination. Our results suggest that vaccinating multiple cohorts produced markedly faster direct/herd effects, and it added benefits that last for 20-70 years. Furthermore, the number needed to vaccinate to prevent 1 anogential warts (AGW) case or cervical cancer (CC) was similar for routine + catch-up (AGW = 9.9, CC = 678) and routine-only vaccination (AGW = 9.9, CC = 677), thus providing similar levels of efficiency per person vaccinated.
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  anogenital warts; cervical cancers; human papillomavirus; mathematical modeling; vaccination

Mesh：

Substances：

Year:  2017        PMID： 28968800      PMCID： PMC5853481          DOI： 10.1093/infdis/jix476

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  12 in total

1.  Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study.

Authors:  Gabriella M Anic; Ji-Hyun Lee; Heather Stockwell; Dana E Rollison; Yougui Wu; Mary R Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto José C Silva; Maria L Baggio; Manuel Quiterio; Jorge Salmerón; Martha Abrahamsen; Anna R Giuliano
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

2.  Development and duration of human papillomavirus lesions, after initial infection.

Authors:  Rachel L Winer; Nancy B Kiviat; James P Hughes; Diane E Adam; Shu-Kuang Lee; Jane M Kuypers; Laura A Koutsky
Journal:  J Infect Dis       Date:  2005-01-21       Impact factor: 5.226

Review 3.  Sexual behaviour in context: a global perspective.

Authors:  Kaye Wellings; Martine Collumbien; Emma Slaymaker; Susheela Singh; Zoé Hodges; Dhaval Patel; Nathalie Bajos
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

4.  Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.

Authors:  Louise Baandrup; Maria Blomberg; Christian Dehlendorff; Carsten Sand; Klaus K Andersen; Susanne K Kjaer
Journal:  Sex Transm Dis       Date:  2013-02       Impact factor: 2.830

5.  Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.

Authors:  Laia Bruni; Mireia Diaz; Leslie Barrionuevo-Rosas; Rolando Herrero; Freddie Bray; F Xavier Bosch; Silvia de Sanjosé; Xavier Castellsagué
Journal:  Lancet Glob Health       Date:  2016-07       Impact factor: 26.763

Review 6.  Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.

Authors:  Talía Malagón; Mélanie Drolet; Marie-Claude Boily; Eduardo L Franco; Mark Jit; Jacques Brisson; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2012-08-22       Impact factor: 25.071

7.  Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Authors:  Nicolas Van de Velde; Marie-Claude Boily; Mélanie Drolet; Eduardo L Franco; Marie-Hélène Mayrand; Erich V Kliewer; François Coutlée; Jean-François Laprise; Talía Malagón; Marc Brisson
Journal:  J Natl Cancer Inst       Date:  2012-10-27       Impact factor: 13.506

8.  Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.

Authors:  Elaine W Flagg; Robert Schwartz; Hillard Weinstock
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

9.  Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Authors:  Simon R M Dobson; Shelly McNeil; Marc Dionne; Meena Dawar; Gina Ogilvie; Mel Krajden; Chantal Sauvageau; David W Scheifele; Tobias R Kollmann; Scott A Halperin; Joanne M Langley; Julie A Bettinger; Joel Singer; Deborah Money; Dianne Miller; Monika Naus; Fawziah Marra; Eric Young
Journal:  JAMA       Date:  2013-05-01       Impact factor: 56.272

Review 10.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2015-03-03       Impact factor: 25.071
View more
  7 in total

1.  Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women.

Authors:  Molly A Feder; Shalini L Kulasingam; Nancy B Kiviat; Constance Mao; Erik J Nelson; Rachel L Winer; Hilary K Whitham; John Lin; Stephen E Hawes
Journal:  J Womens Health (Larchmt)       Date:  2019-07-02       Impact factor: 2.681

2.  Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States.

Authors:  Jean-François Laprise; Harrell W Chesson; Lauri E Markowitz; Mélanie Drolet; Dave Martin; Élodie Bénard; Marc Brisson
Journal:  Ann Intern Med       Date:  2019-12-10       Impact factor: 25.391

3.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

4.  Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus.

Authors:  Mark Jit; Marc Brisson
Journal:  Int J Cancer       Date:  2018-03-01       Impact factor: 7.396

Review 5.  The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Authors:  Cyra Patel; Julia Ml Brotherton; Alexis Pillsbury; Sanjay Jayasinghe; Basil Donovan; Kristine Macartney; Helen Marshall
Journal:  Euro Surveill       Date:  2018-10

Review 6.  Policy Considerations to Promote Equitable Cervical Cancer Screening and Treatment in Peru.

Authors:  Andrea Thoumi; Sarah J Bond; Mary Elizabeth Dotson; Marlee Krieger; Patricia J Garcia; Nirmala Ramanujam
Journal:  Ann Glob Health       Date:  2021-11-24       Impact factor: 2.462

7.  Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination.

Authors:  Julia Ml Brotherton
Journal:  Papillomavirus Res       Date:  2019-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.